uniQure (NASDAQ:QURE) Stock Price Expected to Rise, Mizuho Analyst Says

uniQure (NASDAQ:QUREGet Free Report) had its price target boosted by research analysts at Mizuho from $7.00 to $20.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “neutral” rating on the biotechnology company’s stock. Mizuho’s price objective would suggest a potential upside of 17.79% from the stock’s previous close.

QURE has been the topic of several other research reports. Stifel Nicolaus boosted their target price on uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research report on Monday, December 16th. The Goldman Sachs Group upped their price objective on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $20.00 to $52.00 in a report on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of uniQure in a research note on Tuesday, December 10th. Finally, Royal Bank of Canada increased their price target on shares of uniQure from $14.00 to $20.00 and gave the company an “outperform” rating in a report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $33.88.

Read Our Latest Analysis on QURE

uniQure Stock Performance

NASDAQ:QURE opened at $16.98 on Thursday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The firm has a market cap of $827.66 million, a price-to-earnings ratio of -3.42 and a beta of 0.89. The firm’s fifty day moving average price is $8.13 and its 200 day moving average price is $6.76. uniQure has a 1-year low of $3.73 and a 1-year high of $17.71.

uniQure (NASDAQ:QUREGet Free Report) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $2.29 million for the quarter, compared to the consensus estimate of $2.73 million. On average, sell-side analysts expect that uniQure will post -3.82 EPS for the current year.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $7.63, for a total value of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. RTW Investments LP acquired a new stake in shares of uniQure in the third quarter worth $49,000. China Universal Asset Management Co. Ltd. boosted its position in uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,663 shares during the period. Atria Investments Inc acquired a new stake in uniQure during the 3rd quarter worth about $53,000. Quarry LP purchased a new position in uniQure during the 3rd quarter valued at about $58,000. Finally, Vanguard Personalized Indexing Management LLC lifted its position in shares of uniQure by 21.0% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

(Get Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

See Also

Analyst Recommendations for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.